Ann Rheum Dis 70:1347-1348 doi:10.1136/ard.2010.146878
  • Letters

The efficacy of canakinumab in the treatment of a patient with familial Mediterranean fever and longstanding destructive arthritis

  1. Konstantinos Ritis1
  1. 1First Department of Internal Medicine, Democritus University of Thrace, Alexandroupolis, Greece
  2. 2Department of Radiology, Democritus University of Thrace, Alexandroupolis, Greece
  3. 3Department of Pathophysiology, Medical School, National University of Athens, Athens, Greece
  1. Correspondence to Dr Konstantinos Ritis, University Hospital of Alexandroupolis, Dragana, Alexandroupolis, Greece; kritis{at}
  • Accepted 23 January 2011
  • Published Online First 22 February 2011

Self-limited, non-destructive arthritis is a common clinical presentation of familial Mediterranean fever (FMF), while protracted, refractory to standard treatment arthritis is a rare manifestation of the disease, potentially resulting in severe damage and disability.1,,3

We report on a 25-year-old woman with FMF, homozygous for the MEFV gene M694V mutation, and with longstanding articular involvement affecting her hips and her left knee, effectively treated with canakinumab. She had been under treatment with colchicine since the age of 5. In 2005, she experienced long-lasting arthritis of her right hip and treatment with anakinra (100 mg/day) was added. Anakinra was discontinued shortly afterwards due to severe injection site reactions, precluding the evaluation of its efficacy. She was switched to treatment with etanercept (25 mg twice weekly) and low dose prednisone (5–7.5 mg/day). In 2008, she developed destructive arthritis of the right hip, which lead to total hip replacement, and chronic arthritis of her left knee. Methotrexate (10 mg/week) was added to the existent treatment. Long-term remission was not achieved, as indicated by the clinical findings and the elevated inflammatory …

Free sample This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of ARD.
View free sample issue >>

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

Navigate This Article